EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood eosinophils in COPD: are biologics for everyone?

Marco Vanetti iD, Dina Visca iD, Francesco Ardesi iD, Antonia M Taglioretti, Martina Zappa, Patrizia Pignatti, Antonio Spanevello

Therapeutic Advances in Respiratory Disease · 2026

DOI: 10.1177/17534666261471839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Marco Vanetti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Via Crotto Roncaccio 16, Tradate 21049, Italy. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Eosinophils, Biological Products. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ministero della salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation.

Objectives

To evaluate the prevalence of stable COPD patients who may be eligible for T2 biologics.

Design

Real-world, retrospective, monocentric study in COPD patients undergoing inpatient pulmonary rehabilitation.

Methods

Clinical, functional, and inflammatory data were collected. Patients were considered eligible for T2 biologic therapy whether they were receiving optimized inhaled therapy and had a history of ⩾2 moderate and/or ⩾1 severe exacerbations in the previous year, together with a blood eosinophil count ⩾300 cells/μL.

Results

Among 441 patients, 21.5% had blood eosinophil counts ⩾300 cells/μL and 6.8% fulfilled the combined eligibility criteria. A high burden of respiratory and cardiometabolic comorbidities and increased cardiovascular risk was observed in the overall population.

Conclusion

Only a subgroup of patients seems eligible for biologics, treatment escalation should be based on optimized standard care management and patient phenotyping

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveEosinophilsBiological ProductsHumansFemaleRetrospective StudiesAgedMaleMiddle AgedLeukocyte CountTreatment OutcomePatient Selection

Stichwörter der Autor:innen

COPDbiologicsbiomarkerseosinophiltype-2 inflammation

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Via Crotto Roncaccio 16, Tradate 21049, Italy.
  • Department of Medicine and Surgery, University of Insubria, via Ravasi 2, Varese 21100, Italy.
  • Department of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
  • Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Allergy and Immunology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.

ORCID-Profile: Marco Vanetti, Dina Visca, Francesco Ardesi

Förderung

  • ministero della salute

Zitieren

APA

Vanetti, M., Visca, D., Ardesi, F., Taglioretti, A. M., Zappa, M., Pignatti, P., & Spanevello, A. (2026). Blood eosinophils in COPD: are biologics for everyone?. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261471839

Vancouver

Vanetti M, Visca D, Ardesi F, Taglioretti AM, Zappa M, Pignatti P, et al. Blood eosinophils in COPD: are biologics for everyone?. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261471839

BibTeX
@article{Vanetti2026,
  author = {Vanetti, Marco and Visca, Dina and Ardesi, Francesco and Taglioretti, Antonia M and Zappa, Martina and Pignatti, Patrizia and Spanevello, Antonio},
  title = {Blood eosinophils in COPD: are biologics for everyone?},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  doi = {10.1177/17534666261471839}
}
Kostenlos starten →